

BILL SUMMARY
2nd Session of the 57th Legislature

Bill No.:	HB3418
Version:	CS
Request Number:	11451
Author:	Rep. McEntire
Date:	3/3/2020
Impact:	None

Research Analysis

The CS to HB 3418 exempts the distribution of dialysate or peritoneal dialysis devices used for treating end-stage renal disease (ESRD) from the Oklahoma Pharmacy Act. However, dispensing facilities must ensure that the products are FDA-approved, held by a licensed manufacturer, delivered in original packaging, delivered pursuant to a prescription, and delivered directly to the patient or health care provider responsible for administering the dialysis therapy. Products do not need to be certified by a pharmacist prior to delivery.

Prepared By: Anna Rouw

Fiscal Analysis

The CS to HB 3418 has no costs anticipated to the agency.

Prepared By: Stacy Johnson

Other Considerations

None.